Replies to post #151630 on Biotech Values

[zipjet]

I think BIIB would be wise to price BG-12 below Gilenya and above Copaxone.

Agree.

If the premium to Copaxone is small, patients will move to BG12 and insurers will pick up coverage quickly and not use copays to discourage use.